Historically a frothy stock which has seen some spectacular but short-lived rises in the SP.
Current SP of 0.025 gives a market capital of some $17 mill.
Holders still dreaming of the glory days – there was only a couple! – of late 2010 when the price surged from 0.022-ish to intra-day high of 0.105.
Product line revolves around developing diagnostics using a candidate cancer marker called ‘midkine’.
And wait there’s more: also manufactures and markets a hair restorant retail product called ‘Evolis’.
But no steak knives, that I know of. 
Recent days are a new experience for CDY holders: a slow and steady build-up of interest, based on news of collaborations with some serious larger biotechs in the diagnostic area, and some relatively healthy financial numbers.
Having made a motsa day-trading CDY during it’s brief splurge a couple of years ago, I’ve watched it keenly since. While I have difficulty taking hair-restorant seriously, I have to say CDY is looking a lot more interesting recently.
Worth watching also are options CDYO, exercise date Oct 2016, conversion 0.034, currently trading at 0.008 ish.
Discl: don’t hold.
Discl: I am beyond the range of any hair restorant.
Be the first to comment